[1] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.临床肝胆病杂志,2015,31:1752 -17692. [2] Watkins PB,Seligman Pj,Pears Js,et al.Using controlled clinical trails to leran more about acute drug-induced liver injury.Hepatology,2008,48:1680-1689. [3] Shen T, Liu Y, Shang J, et al.Incidence and etiology of drug-induced liver injury in Mainland China.Gastroenterology,2019,156:2230-2241. [4] Chitturi S,Farrell GC.Identifying who is at risk of drug-induced liver injury: Is human leukocyte antigen specificity the key.Hepatology, 2011, 53:359-362. [5] Cho J,Kim L, Li Z,et al.Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6. PLoS ONE, 2013,8:e61186. [6] Wong MCS,Huang JLW,George J,et al.The changing epidemiol-ogy of liver diseases in the Asia-Pacific region.Nat Rev Gastroen-terol Hepatol,2019,16:57-73. [7] Zhou, Yuan,Yang,et al.Epidemiology of drug-induced liver injury in China: a systematic;analysis of the Chinese literature including 21 789 patients.European Journal of Gastroenterology & Hepatology, 2013, 25:825-829. [8] 朱春雾,王海南,袁继丽,等.445例药物性肝损伤的临床分析.临床肝胆病杂志,2018,34:354-358. [9] Wang Z,Liang X,Yu J,et al.Non-genetic risk factors and predicting efficacy for docetaxel—drug-induced liver injury among metastatic breast cancer patients.J Gastroenterol Hepatol,2012,27:1348-1352. [10] Zhang C,Wu Y,Yuan S,et al.Characteristics of drug-induced liver injury in Northeast China:disease spectrum and drug types.Dig Dis Sci,2020,6:1-9. [11] Pronovost P,Weast B,Schwarz M ,et al.M edication reconcilia-tion:a practicaltoolto reducetherisk ofmedication errors.J Crit Care,2003,18:201-205. [12] 李娟,张成志,陈庆宪,等.17个省(区、市)56家“三甲”医院医务人员及患者对临床药师的需求及评价调查.中国药房,2018,29:1136-1139. [13] Rockey DC,Seeff LB,Rochon J,et al.Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method,2010,51:2117-2126. |